



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

URI SAGMAN
MICHAEL G. ROSENBLUM
LON J. WILSON
MICHAEL ALFORD

Serial No.: 10/623,190

Filed: July 18, 2003

For: FULLERENES IN TARGETED
THERAPIES

Group Art Unit: 1616

Examiner: Unknown

Attorney Docket: 4451.000800/RFE

CUSTOMER NO. 23720

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

CERTIFICATE OF MAILING (37 C.F.R. § 1.8)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date below.

December 3, 2003


Cynde Meinhart

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be


an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Director is hereby authorized to deduct said fees from Williams, Morgan & Amerson, P.C., Deposit Account No. 50-0786/4451.000800RFE.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

WILLIAMS, MORGAN & AMERSON, P.C.
CUSTOMER NO. 23720

A handwritten signature in black ink, appearing to read "Raymund F. Eick", is written over a horizontal line.

Raymund F. Eick, Ph.D.
Reg. No. 42,508
10333 Richmond, Suite 1100
Houston, Texas 77042
(713) 934-4065
(713) 934-7011 (fax)

AGENT FOR APPLICANTS

December 3, 2003

Form PTO-1449 (modified)

Atty. Docket No.
4451.000800/RFESerial No.
10/623,190

List of Patents and Publications for Applicant's

Applicants

Uri Sagman/Michael G. Rosenblum/Lon J. Wilson/
Michael Alford

INFORMATION DISCLOSURE STATEMENT

Filing Date:

July 18, 2003

Group:

1616

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2002/0049495	04/25/2002	Kutryk et al.	623	1.47	03/15/2001
	A2						
	A3						

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1						
	B2						
	B3						

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Brettreich et al., <i>Angew. Chem. Int. Ed.</i> 39:1845-1848 (2000)
	C2	Holzinger et al., <i>Angew. Chem. Int. Ed.</i> 40:4002-4005 (2001)
	C3	Köhler et al., <i>Nature</i> 256:495-497 (1975)
	C4	Campbell, "Monoclonal Antibody Technology, The Production and Characterization of Rodent and Human Hybridomas," <i>Lab. Tech. in Biochem. & Mol. Biol.</i> , Vol. 13 (1984)
	C5	Huse et al., <i>Science</i> 246:1275-1281 (1989)
	C6	Kantor et al., <i>Hybridoma</i> 1:473-482 (1982)
	C7	Morgan et al., <i>Hybridoma</i> 1:27-36 (1981)
	C8	Wilson et al., <i>Int. J. Cancer</i> 28:293-300 (1981)
	C9	Macey et al., <i>Am. J. of Physiologic Imaging</i> 3:1-6 (1988)
	C10	Koizumi et al., <i>Jpn. J. Cancer Res.</i> 79:973-981 (1988)
	C11	Williams et al., <i>Cancer Res.</i> 50:974s-979s (1990)

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)		Atty. Docket No. 4451.000800/RFE	Serial No. 10/623,190
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants Uri Sagman/Michael G. Rosenblum/Lon J. Wilson/ Michael Alford	
		Filing Date: July 18, 2003	Group: 1616
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C12	Rowlinson-Busza et al., <i>Current Opin. Oncol.</i> 4:1142-1148 (1992)
	C13	Wahl, <i>Cancer</i> 73:989-992 (1994)
	C14	Stirpe et al., <i>J. Biol. Chem.</i> 255:6947-6953 (1980)
	C15	

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.